自体造血干细胞移植治疗成人急性白血病的研究进展
- 1 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020
- 2 天津医学健康研究院,天津 301600
摘要
Advancements in autologous hematopoietic stem cell transplantation in the treatment of adult acute leukemia
- 1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
- 2 Tianjin Institute of Health Science,Tianjin 301600, China
Abstract
Autologous hematopoietic stem cell transplantation (ASCT) is a critical therapeutic modality that restores hematopoietic and immune functions through the reinfusion of a patient's own hematopoietic stem cells. Since its development in the 1980s, this technique has been widely applied in the treatment of various hematologic malignancies, including acute leukemia (AL). It has significantly prolonged disease-free survival (DFS) and enabled some patients to achieve a clinical cure. Furthermore, ASCT has demonstrated significant advantages in shortening treatment duration, reducing medical costs, and improving quality of life. In recent years, with the rapid advancement of novel diagnostic and therapeutic technologies — such as minimal residual disease (MRD) monitoring, small-molecule targeted agents, and immunotherapy — the ASCT treatment protocol has been continuously optimized, leading to steadily improving clinical efficacy. This article reviews the research progress of ASCT in the treatment of adult patients with AL, focusing on the optimization of indications, innovations in conditioning regimens, and integration with novel therapeutic strategies, with the aim of providing a reference for clinical practice.
